Compare DHC & HUMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DHC | HUMA |
|---|---|---|
| Founded | 1998 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 165.7M |
| IPO Year | 1998 | 2020 |
| Metric | DHC | HUMA |
|---|---|---|
| Price | $7.62 | $0.60 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 8 |
| Target Price | ★ $8.00 | $6.19 |
| AVG Volume (30 Days) | 1.3M | ★ 10.1M |
| Earning Date | 05-04-2026 | 05-15-2026 |
| Dividend Yield | ★ 0.53% | N/A |
| EPS Growth | 23.23 | ★ 79.37 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,074,819,000.00 | $2,038,000.00 |
| Revenue This Year | $3.13 | $444.16 |
| Revenue Next Year | $7.00 | $248.39 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 1.59 | N/A |
| 52 Week Low | $3.93 | $0.53 |
| 52 Week High | $9.66 | $2.55 |
| Indicator | DHC | HUMA |
|---|---|---|
| Relative Strength Index (RSI) | 35.18 | 43.08 |
| Support Level | $6.92 | $0.54 |
| Resistance Level | $9.66 | $0.75 |
| Average True Range (ATR) | 0.24 | 0.05 |
| MACD | -0.01 | -0.00 |
| Stochastic Oscillator | 25.86 | 12.91 |
Diversified Healthcare Trust is a real estate investment trust that focuses on healthcare-related properties, including life science estates, medical offices, and senior living communities. It acquires and owns properties and is engaged in the development and implementation of medical services and technologies. The company has two reportable segments: SHOP (Senior Housing Operating Portfolio) and Medical Office and Life Science Portfolio. The SHOP segment includes managed senior living communities providing residential living and care services. The Medical Office and Life Science Portfolio segment consists of properties leased to medical providers and biotechnology laboratories. It generates the majority of its revenue from the SHOP segment.
Humacyte Inc is developing a commercial-stage biotechnology platform to deliver universally implantable bioengineered human tissues and organs designed to improve the lives of patients and transform the practice of medicine. It develops and manufactures acellular tissues to treat a wide range of diseases, injuries, and chronic conditions. Company's pipeline includes Vascular Trauma, PAD, Dailysis, Acellular Tissue Engineered Vessels, Organ Systems, Advanced Tissue Constructs.